Neonatal chylothorax: Aetiology, clinical course and efficacy of treatment;Quilotórax neonatal: Etiología, evolución y respuesta al tratamiento

Anales de Pediatria

Volumn 68, Issue 3, 2008, Pages 224-231

  Copons Fernandez C ^a   Benitez Segura I ^a   Castillo Salinas, F ^a   Salcedo Abizanda, S ^a  

^a HOSPITAL MATERNO INFANTIL VALL D HEBRON   (Spain)

Author keywords

Chylothorax; Congenital diaphragmatic hernia; Congenital heart disease; Hypoalbuminaemia; Mortality; Octreotide; Outcome; Pleural effusion

Indexed keywords

OCTREOTIDE;

ABSENCE OF SIDE EFFECTS; ARTICLE; CHYLOTHORAX; CLINICAL ARTICLE; CONFIDENCE INTERVAL; CONGENITAL DIAPHRAGM HERNIA; CONGENITAL HEART DISEASE; DISEASE COURSE; DRUG EFFICACY; FOLLOW UP; HUMAN; INCIDENCE; MORTALITY; NEWBORN; NEWBORN INTENSIVE CARE; OUTCOME ASSESSMENT; PROSPECTIVE STUDY; TERTIARY HEALTH CARE; THORAX SURGERY; TOTAL PARENTERAL NUTRITION; TREATMENT RESPONSE;

EID: 41549144811     PISSN: 16954033     EISSN: 16959531     Source Type: Journal    
DOI: 10.1157/13116701     Document Type: Article

References (30)

1. Beghetti M, La Scala G, Belli D, Bugmann P, Kalangos A, Le Coultre C. Etiology and management of pediatric chylothorax. J Pediatr. 2000;136:653-8.
2. Martínez Tallo E, Hernández Rastrollo R, Agulla Rodiño E, Sanjuán Rodríguez S, Campello Escudero E. Quilotórax neonatal y tratamiento conservador. An Esp Pediatr. 2002;56:448-51.
3. Buttiker V, Fanconi S, Burger R. Chylothorax in children: Guidelines for diagnosis and management. Chest. 1999;116:682-7.
4. Dubin PJ, King IN, Gallagher PG. Congenital chylothorax. Curr Opin Pediatr. 2000;12:505-9.
5. Cannizzaro V, Frey B, Bernet-Buettiker V. The role of somatostatin in the treatment of persistent chylothorax in children. Eur J Cardiothorac Surg. 2006;30:49-53.
6. Rocha G, Fernandes P, Rocha P, Quintas C, Martins T, Proenca E. Pleural effusions in the neonate. Acta Paediatr. 2006;95:791-8.
7. Chan EH, Russell JL, Williams WG, Van Arsdell GS, Coles JG, McCrindle BW. Postoperative chylothorax after cardiothoracic surgery in children. Ann Thorac Surg. 2005;80:1864-70.
8. Van Straaten HL, Gerards LJ, Krediet TG. Chylothorax in the neonatal period. Eur J Pediatr. 1993;152:2-5.
9. Roehr CC, Jung A, Proquitte H, Blankenstein O, Hammer H, Lakhoo K, et al. Somatostatin or octreotide as treatment options for chylothorax in young children: a systematic review. Intensive Care Med. 2006;32:650-7.
10. Stringel G, Mercer S, Bass J. Surgical management of persistent postoperative chylothorax in children. Can J Surg. 1984;27:543-6.
11. Lim KA, Kim SH, Huh J, Kang IS, Lee HJ, Jun TG, et al. Somatostatin for postoperative chylothorax after surgery for children with congenital heart disease. J Korean Med Sci. 2005;20:947-51.
12. Bond SJ, Guzzetta PC, Snyder ML, Randolph JG. Management of pediatric postoperative chylothorax. Ann Thorac Surg. 1993;56:469-72.
13. Kavvadia V, Greenough A, Davenport M, Karani J, Nicolaides KH. Chylothorax after repair of congenital diaphragmatic hernia: Risk factors and morbidity. J Pediatr Surg. 1998;33:500-2.
14. Al-Tawil K, Ahmed G, Al-Hathal M, Al-Jarallah Y, Campbell N. Congenital chylothorax. Am J Perinatol. 2000;17:121-6.
15. Fernández Álvarez JR, Kalache KD, Grauel EL. Management of spontaneous congenital chylothorax: Oral medium-chain triglycerides versus total parenteral nutrition. Am J Perinatol. 1999;16:415-20.
16. Buettiker V, Hug MI, Burger R, Baenziger O. Somatostatin: A new therapeutic option for the treatment of chylothorax. Intensive Care Med. 2001;27:1083-6.
17. Rosti L, De Battisti F, Butera G, Cirri S, Chessa M, Delogu A, et al. Octreotide in the management of postoperative chylothorax. Pediatr Cardiol. 2005;26:440-3.
18. Miles JM, Cattalini M, Sharbrough FW, Wold LE, Wharen RE Jr, Gerich JE, et al. Metabolic and neurologic effects of an intravenous medium-chain triglyceride emulsion. JPEN J Parenter Enteral Nutr. 1991;15:37-41.
19. Kalomenidis I. Octreotide and chylothorax. Curr Opin Pulm Med. 2006;12:264-7.
20. Lamberts SW, Van der Lely AJ, Hofland LJ. New somatostatin analogs: will they fulfill old promises? Eur J Endocrinol. 2002;146:701-5.
21. Lam JC, Aters S, Tobias JD. Initial experience with octreotide in the pediatric population. Am J Ther. 2001;8:409-15.
22. Mohseni-Bod H, Macrae D, Slavik Z. Somatostatin analog (octreotide) in management of neonatal postoperative chylothorax: is it safe? Pediatr Crit Care Med. 2004;5:356-7.
23. Allen EM, Van Heeckeren DW, Spector ML, Blumer JL. Management of nutritional and infectious complications of postoperative chylothorax in children. J Pediatr Surg. 1991;26:1169-74.
24. Hargus EP, Carson SD, McGrath RL, Wolfe RR, Clarke DR. Chylothorax and chylopericardial tamponade following Blalock-Taussig anastomosis. J Thorac Cardiovasc Surg. 1978;75:642-5.
25. Le Coultre C, Oberhansli I, Mossaz A, Bugmann P, Faidutti B, Belli DC. Postoperative chylothorax in children: differences between vascular and traumatic origin. J Pediatr Surg. 1991;26:519-23.
26. Murphy MC, Newman BM, Rodgers BM. Pleuroperitoneal shunts in the management of persistent chylothorax. Ann Thorac Surg. 1989;48:195-200.
27. Selle JG, Snyder WH 3rd, Schreiber JT. Chylothorax: indications for surgery. Ann Surg. 1973;177:245-9.
28. Brissaud O, Desfrere L, Mohsen R, Fayon M, Demarquez JL. Congenital idiopathic chylothorax in neonates: chemical pleurodesis with povidone-iodine (Betadine). Arch Dis Child Fetal Neonatal Ed. 2003;88:F531-3.
29. Rheuban KS, Kron IL, Carpenter MA, Gutgesell HP, Rodgers BM. Pleuroperitoneal shunts for refractory chylothorax after operation for congenital heart disease. Ann Thorac Surg. 1992;53:85-7.
30. Puntis JW, Roberts KD, Handy D. How should chylothorax be managed? Arch Dis Child. 1987;62:593-6.